In addition to its role in blood clot formation, thrombin plays an important role in initiating vascular and cellular changes that promote inflammation, revascularization, and wound healing. We have shown that he thrombin peptide TRAP-508 activates cell surface receptors, stimulates wound healing, and recruits neutrophils to the wound site. We therefore postulated that TRAP-508-based wound management products may activate natural, cellular, antimicrobial action to aid in healing and help prevent or control wound infection. Phase I studies demonstrated that a single topical application of TRAP-508 recruited neutrophils to the site of injury. In addition, in vitro studies showed that this peptide has direct chemotactic and phagocytic activation effects on human neutrophils. We will now prepare product formulations with TRAP-508 for development of sprays, ointments, and bandages and conduct safety, stability, and efficacy tests of these formulations to proceed through regulatory approval, initiation of clinical trials, and market entry. Wound healing products that work through natural mechanisms and are inexpensive have an enormous market potential and may be able to alleviate much of the pain and suffering associated with chronic or infected wounds that fail to heal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI038153-02
Application #
2004283
Study Section
Special Emphasis Panel (ZRG5-MBC-2 (01))
Project Start
1995-04-01
Project End
1999-02-28
Budget Start
1997-03-01
Budget End
1998-02-28
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Chrysalis Biotechnology, Inc.
Department
Type
DUNS #
City
Galveston
State
TX
Country
United States
Zip Code
77550